Research · Sep 3, 2026
[LIVN] LivaNova Thesis 2026: Neuromodulation VNS and Cardiopulmonary Specialty Compounder
LivaNova plc (NASDAQ: LIVN), headquartered in London-UK, is a Neuromodulation-VNS-and-Cardiopulmonary + emerging-multi-cycle-VNS-Depression-Cardiopulmonary-and-Difficult-to-Treat-Depression-Cycle leader providing distinctive multi-cycle Neuromodulation-VNS-Epilepsy + emerging-VNS-Difficult-to-Treat-Depression + emerging-Cardiopulmonary-Heart-Lung-Machine + emerging-Adjacent-Heart-Failure-and-Hypertension services to substantial multi-cycle Epilepsy-Neurology-VNS-Implant-Patient + multi-cycle-emerging-Difficult-to-Treat-Depression-VNS-Patient + multi-cycle-emerging-Cardiopulmonary-Hospital-Cardiac-Surgery-Customer + multi-cycle-emerging-Heart-Failure-and-Hypertension-Patient + multi-cycle-emerging-International-Europe-and-Asia-Pacific-Hospital customer base. The company has distinctive multi-cycle LivaNova-and-London-UK-and-Neuromodulation-and-Cardiopulmonary heritage: founded 2015 as LivaNova-via-Sorin-and-Cyberonics-merger ($2.7B+ combined enterprise providing Neuromodulation-VNS-and-Cardiopulmonary-Scale + 1979-Cyberonics-Houston-TX-historical-VNS-Founder-Reese-Terry + 1956-Sorin-Italy-historical-Cardiopulmonary-Founder); 2015 substantial NASDAQ LivaNova-Merger-IPO; 2018 substantial CardiacRhythm-Management-CRM-Divestment (~$200M divest to MicroPort); 2020 substantial Heart-Failure-and-Hypertension-Pipeline-Acquisition; 2021-2024 substantial Multi-Cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Investment; 2024 substantial CEO-Succession-Vladimir-Makatsaria-from-Damien-McDonald-Former-CEO + Multi-Cycle-VNS-Difficult-to-Treat-Depression-Strategy-Acceleration; multi-cycle-disciplined-Neuromodulation-VNS-and-Cardiopulmonary-Pipeline-Investment; Vladimir-Makatsaria-CEO-since-2024 + Multi-Cycle-MedTech-Cardio-and-Neuromodulation-Strategy. FY2025 closes with selected various aggregate revenue ~$1.15-1.30B (~3-8% YoY-reflecting Neuromodulation-VNS-Epilepsy-and-Cardiopulmonary-Cycle + emerging-multi-cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Readout-Anticipation + emerging-International-Expansion), adjusted EBITDA ~$215-275M (~19-22% margins), adjusted EPS ~$2.60-3.45, net debt ~$0.40-0.55B (~1.5-2.2x leverage), and ~53-55M shares outstanding under President & CEO Vladimir Makatsaria (since-2024). The Neuromodulation-VNS-Epilepsy-and-Cardiopulmonary-Heart-Lung-Machine franchise deep-dive covers distinctive multi-cycle ~3,000-3,200 employees + ~London-UK-HQ + ~Houston-TX-VNS-Cyberonics-historical-and-Mirandola-Italy-Cardiopulmonary-Sorin-historical-Globally-Positioned-Manufacturing-Facility, Neuromodulation-VNS ~37-42% revenue + Cardiopulmonary ~55-61% revenue + ACS-and-Adjacency ~2-7% revenue, substantial multi-cycle Epilepsy-Neurology-VNS-Implant-Patient (~500,000+ Drug-Resistant-Epilepsy-Patient-Population-US) + Difficult-to-Treat-Depression-VNS-Patient (~5M+ Difficult-to-Treat-Depression-Patient-Population-US) + Cardiopulmonary-Hospital-Cardiac-Surgery-Customer + International-Europe-and-Asia-Pacific-Hospital customer base, 2015-NASDAQ-LivaNova-Sorin-Cyberonics-Merger-IPO + 2018-CRM-Divestment + 2020-Heart-Failure-and-Hypertension-Pipeline-Acquisition + 2021-2024-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Investment + 2024-CEO-Succession transformational-platform, emerging-multi-cycle Neuromodulation-VNS-Epilepsy-Demand + emerging-VNS-Difficult-to-Treat-Depression-CMS-NCD-Coverage-and-Pivotal-RECOVER-Trial-2024-Readout + emerging-Cardiopulmonary-Heart-Lung-Machine-Demand + emerging-Heart-Failure-and-Hypertension-Adjacency + emerging-International-Hospital-Demand structural-tailwinds, competing in Neuromodulation-VNS space with Medtronic, Boston Scientific, Abbott, Nevro, inspire-Medical-Systems, Axonics; Cardiopulmonary space with Maquet/Getinge, Terumo, Medtronic-Cardiopulmonary, Edwards Lifesciences; and private-equity-Carlyle-Apollo-KKR-Blackstone-Bain-CD&R-EQT-Permira-CVC-Bridgepoint-Cinven-Ardian-TPG-Veritas-Genstar-Hellman-Friedman. The Vladimir-Makatsaria + 2024-CEO-succession + 2015-Sorin-Cyberonics-Merger-and-2024-RECOVER-Pivotal-Trial-Readout deep-dive covers Vladimir-Makatsaria-CEO (since-2024 + Former-Johnson-Johnson-MedTech-veteran) expertise, multi-cycle-disciplined-Neuromodulation-VNS-and-Cardiopulmonary-Pipeline-Investment discipline, no-dividend (Cash-Flow-Reinvested-in-R&D-and-Pipeline) + multi-cycle-emerging-share-buyback-only (~$25-100M/yr discretionary). Capital position is IG-equivalent (Baa3/BBB- ~1.5-2.2x leverage). At ~$45-65 per share, equity value ~$2.40-3.55B, EV ~$2.80-4.10B, providing ~17-25x EPS and ~10-15x EV/EBITDA.